These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3797460)

  • 1. [Antithrombin III-level in plasma preparations and coagulation active plasma fractions].
    Tausendfreund K; Uteg KH; Günther E
    Pharmazie; 1986 Sep; 41(9):662-3. PubMed ID: 3797460
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 3. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children.
    Hanada T; Abe T; Takita H
    Am J Pediatr Hematol Oncol; 1985; 7(1):3-8. PubMed ID: 4037242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dosage recommendations for substitution of antithrombin III with coagulation-active human citrated plasma].
    Hinsenbrock KP; Neumann B; Sitarek U
    Anaesthesiol Reanim; 1988; 13(5):281-5. PubMed ID: 3178982
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of an automated analyzer in the evaluation of antithrombin III and heparin.
    Scully MF
    Semin Thromb Hemost; 1983 Oct; 9(4):309-20. PubMed ID: 6658462
    [No Abstract]   [Full Text] [Related]  

  • 6. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-thormbin III and heparin clotting times in thrombosis and atherosclerosis.
    O'Brien JR
    Thromb Diath Haemorrh; 1974 Sep; 32(1):116-23. PubMed ID: 4454034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The physiological inhibitors of blood coagulation. 1. Antithrombin III (AT III)].
    Kase F; Pospísil J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(3):337-49. PubMed ID: 6194066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between anticoagulant activity and antigenicity of plasma antithrombin III in healthy subjects and patients with disseminated intravascular coagulation (DIC) (author's transl)].
    Matsuda T; Ogawara M; Miura R; Seki T; Yokouchi M; Murakami M; Fujisawa M; Nakanishi K; Nakamura S
    Rinsho Ketsueki; 1980 Mar; 21(3):341-6. PubMed ID: 6157843
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipoprotein fractions and antithrombin III consumption during clotting.
    Winter JH; Bennett B; McTaggart F; Douglas AS
    Thromb Haemost; 1982 Jun; 47(3):236-8. PubMed ID: 7112497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High molecular weight forms of antithrombin III complexes in blood.
    Marciniak E; Gora-Maslak G
    Thromb Haemost; 1983 Feb; 49(1):32-6. PubMed ID: 6845270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antithrombin III in plasma free of anti-hemophilic globulin].
    Lepe-Zúñiga JL; Vázquez de Chávez MC; Pizano-López G
    Bol Med Hosp Infant Mex; 1985 Mar; 42(3):159-63. PubMed ID: 3921040
    [No Abstract]   [Full Text] [Related]  

  • 16. [Alteration in coagulation and fibrinolysis after burn injury and significance of anticoagulation therapy using heparin and antithrombin III concentrate].
    Ono I
    Hokkaido Igaku Zasshi; 1987 Jan; 62(1):108-21. PubMed ID: 3817736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?
    Rodríguez-López JM; del Barrio E; Lozano FS; Muriel C
    Anesth Analg; 2008 Oct; 107(4):1444-5. PubMed ID: 18806070
    [No Abstract]   [Full Text] [Related]  

  • 18. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
    Zaidan JR; Johnson S; Brynes R; Monroe S; Guffin AV
    Anesth Analg; 1986 Apr; 65(4):377-80. PubMed ID: 3954111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antithrombin III substitution in patients in shock].
    Vinazzer H; Blauhut B; Bergmann H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):806-16. PubMed ID: 6083957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.